IPCALAB.NSE

Ipca Laboratories Ltd.

In this briefing: HDFC Bank (HDFCB IN) Tactical Outlook: Hold or Sell? Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market Exencial Indutry Tiding Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts 1. HDFC Bank (HDFCB IN) Tactical Outlook: Hold or Sell? HDFC Bank (HDFCB IN) has been losing steam since last summer. In the last few months the stock started to sell-off, but it did not lose more than 10%. A recent pullback was flagged as oversold by our quantitative model, last Friday. Then the stock started to rally this week. We think the current rally may be a sell opportunity, possibly taking advantage of the stock recent volatility. Selling setups identified by our model are discussed in this insight. 2. Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market The shift to "Agentic AI" could propel the global economy to $500 trillion , provided companies overhaul business architectures to bridge the current gap between tech progress and realized value.

In this briefing: Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market Exencial Indutry Tiding Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate 1. Infosys: The AI-First Services Opportunity- Capturing a $400 Billion Market The shift to "Agentic AI" could propel the global economy to $500 trillion , provided companies overhaul business architectures to bridge the current gap between tech progress and realized value. Through the Topaz Fabric , Infosys is deploying over 600 specialized agents and small language models (SLMs) to help 90% of their top clients move from pilots to production. Success requires navigating the " Brownfield " productivity gap, where legacy systems and data silos currently consume 60-80% of IT budgets , hindering the deployment of high-impact AI solutions. 2.

In this briefing: Exencial Indutry Tiding Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts SignatureGlobal India Ltd - SignatureGlobal’s Leap into Commercial Real Estate Axis PUNCH: Greenply Industries Ltd - 17th February, 2026 1. Exencial Indutry Tiding Bajaj Hindusthan Sugar's sales decline by 6.7% in December 2025 quarter Man-Made filaments & fibres industry's sales grow by 15.2% in December 2025 quarter Personal & home care products industry's sales grow by 5.4% in December 2025 quarter 2. Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Indo-MIM Ltd (1666551D IN) (IML) is looking to raise about US$750m in its upcoming India IPO. IML provides end-to-end solutions for the manufacture of precision engineering components using metal injection molding technology. Its capabilities include mold designing and tooling, coupled with finishing and assembly operations.

In this briefing: Primer: CSL (CSL AT) - Feb 2026 Aequitas: Indo-MIM Pre-IPO - The Positives - Global-Scale Manufacturing Platform Primer: Shenzhen Vmax New Energy Lt (688612 CH) - Feb 2026 Oil futures: Crude lower as Iran says 'understanding' reached with US HSIE Results Daily: IPCA Laboratories, IRB Infra, Galaxy Surfactants, Ahluwalia Contracts 1. Primer: CSL (CSL AT) - Feb 2026 CSL is a global biotechnology leader with a dominant position in plasma-derived therapies ( CSL Behring) and a significant presence in the influenza vaccine market ( CSL Seqirus). The recent acquisition of Vifor Pharma has diversified CSL's portfolio into the attractive markets of nephrology and iron deficiency, providing a new avenue for growth. While facing near-term headwinds from policy changes, competitive pressures, and a recent CEO transition, the company's long-term outlook is supported by a strong R&D pipeline, recovering plasma collections, and strategic cost-saving initiatives. This content is AI-generated and displayed for general informational purposes only.